Cargando…

Prediabetes in Colombia: Expert Consensus

The prevalence of Prediabetes in Colombia is high, and despite being recognized and categorized in the main Medical Guidelines and included in the International Classification of Diseases in Colombia, knowledge and awareness of it is limited amongst healthcare professionals and in the community. Our...

Descripción completa

Detalles Bibliográficos
Autores principales: López-Jaramillo, Patricio, Calderón, Carlos, Castillo, Jorge, Escobar, Iván Darío, Melgarejo, Enrique, Parra, Gustavo Adolfo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Universidad del Valle 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896726/
https://www.ncbi.nlm.nih.gov/pubmed/29662261
http://dx.doi.org/10.25100/cm.v43i4.3662
_version_ 1783313868522520576
author López-Jaramillo, Patricio
Calderón, Carlos
Castillo, Jorge
Escobar, Iván Darío
Melgarejo, Enrique
Parra, Gustavo Adolfo
author_facet López-Jaramillo, Patricio
Calderón, Carlos
Castillo, Jorge
Escobar, Iván Darío
Melgarejo, Enrique
Parra, Gustavo Adolfo
author_sort López-Jaramillo, Patricio
collection PubMed
description The prevalence of Prediabetes in Colombia is high, and despite being recognized and categorized in the main Medical Guidelines and included in the International Classification of Diseases in Colombia, knowledge and awareness of it is limited amongst healthcare professionals and in the community. Our expert group recommends that educational programs emphasize a global approach to risk which includes a recognition of the importance of prediabetes and its evaluation along with and other risk factors such as a family history of DM2, overweight and obesity, dislipidemia and hypertension. Studies conducted in Colombia demonstrate the value of the FINDRIS questionnaire as a tool to identify subjects at risk of prediabetes and DM2, and we recommend that it should be systematic applied throughout the country as part of government policy. Prediabetes progresses to DM2 at an annual rate of 10%, but it has also been shown that prediabetes is an independent risk factor for cardiovascular outcomes. On this basis, the Committee recommends that once prediabetes is detected and diagnosed, immediate management of the disease begins through lifestyle changes, with follow up assessments performed at 3 and 6 months. If the patient does not respond with a weight loss of at least 5% and if the HbA1C values ​​are not normalized, pharmacological management should be initiated with a metformin dose of 500 mg / day, increasing up to 1,500 - 1,700 mg / day, according to tolerance.
format Online
Article
Text
id pubmed-5896726
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Universidad del Valle
record_format MEDLINE/PubMed
spelling pubmed-58967262018-04-16 Prediabetes in Colombia: Expert Consensus López-Jaramillo, Patricio Calderón, Carlos Castillo, Jorge Escobar, Iván Darío Melgarejo, Enrique Parra, Gustavo Adolfo Colomb Med (Cali) Article Review The prevalence of Prediabetes in Colombia is high, and despite being recognized and categorized in the main Medical Guidelines and included in the International Classification of Diseases in Colombia, knowledge and awareness of it is limited amongst healthcare professionals and in the community. Our expert group recommends that educational programs emphasize a global approach to risk which includes a recognition of the importance of prediabetes and its evaluation along with and other risk factors such as a family history of DM2, overweight and obesity, dislipidemia and hypertension. Studies conducted in Colombia demonstrate the value of the FINDRIS questionnaire as a tool to identify subjects at risk of prediabetes and DM2, and we recommend that it should be systematic applied throughout the country as part of government policy. Prediabetes progresses to DM2 at an annual rate of 10%, but it has also been shown that prediabetes is an independent risk factor for cardiovascular outcomes. On this basis, the Committee recommends that once prediabetes is detected and diagnosed, immediate management of the disease begins through lifestyle changes, with follow up assessments performed at 3 and 6 months. If the patient does not respond with a weight loss of at least 5% and if the HbA1C values ​​are not normalized, pharmacological management should be initiated with a metformin dose of 500 mg / day, increasing up to 1,500 - 1,700 mg / day, according to tolerance. Universidad del Valle 2017-12-30 /pmc/articles/PMC5896726/ /pubmed/29662261 http://dx.doi.org/10.25100/cm.v43i4.3662 Text en Copyright © 2017 Universidad del Valle This article is distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Article Review
López-Jaramillo, Patricio
Calderón, Carlos
Castillo, Jorge
Escobar, Iván Darío
Melgarejo, Enrique
Parra, Gustavo Adolfo
Prediabetes in Colombia: Expert Consensus
title Prediabetes in Colombia: Expert Consensus
title_full Prediabetes in Colombia: Expert Consensus
title_fullStr Prediabetes in Colombia: Expert Consensus
title_full_unstemmed Prediabetes in Colombia: Expert Consensus
title_short Prediabetes in Colombia: Expert Consensus
title_sort prediabetes in colombia: expert consensus
topic Article Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896726/
https://www.ncbi.nlm.nih.gov/pubmed/29662261
http://dx.doi.org/10.25100/cm.v43i4.3662
work_keys_str_mv AT lopezjaramillopatricio prediabetesincolombiaexpertconsensus
AT calderoncarlos prediabetesincolombiaexpertconsensus
AT castillojorge prediabetesincolombiaexpertconsensus
AT escobarivandario prediabetesincolombiaexpertconsensus
AT melgarejoenrique prediabetesincolombiaexpertconsensus
AT parragustavoadolfo prediabetesincolombiaexpertconsensus